Featured Research

from universities, journals, and other organizations

Common outcome measures required for neurofibromatosis clinical trials

Date:
December 9, 2013
Source:
Wolters Kluwer Health
Summary:
As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches -- including outcome measures specific to NF -- are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has now been published.

As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches -- including outcome measures specific to NF -- are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology®, the Official Journal of the American Academy of Neurology (AAN). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The (REiNS) Collaboration was formed to achieve consensus regarding the design of clinical trials for treatments of NF and related disorders, with a focus on developing a standard set of appropriate and meaningful outcome measures. "This supplement presents the initial progress of several of the working groups and includes the first series of consensus recommendations for NF clinical trial endpoints by the REiNS International Collaboration," according to an introduction by Dr Scott R. Plotkin and colleagues. The full supplement is freely available on the journal website.

Initial Reports on Consensus Approach to NF Clinical Trials

The REiNS Collaboration was established at the 2011 meeting of the Children's Tumor Foundation. The neurofibromatoses -- NF1, NF2, and schwannomatosis -- are a group of related genetic diseases in which patients are predisposed to developing multiple tumor types, particularly tumors of the nerve sheath. Other manifestations may occur as well, including learning problems in patients with NF1 and cataracts in those with NF2. Especially for NF1, the disease is usually diagnosed in childhood.

Traditionally, surgery has been the standard treatment for NF tumors. But recent advances in scientific understanding of the biology and development of NF have raised the promise of new targeted antitumor agents. An ambitious research agenda has been developed for rapid evaluation of these emerging NF treatments.

Most early NF studies used designs similar to those for cancer treatments. But these research designs -- often focusing on tumor size or overall survival -- may not be relevant to NF. Neurofibromatosis tumors are typically benign, rather than malignant, and patients face unique clinical and functional problems. "The NF community continues to struggle with the optimum design of clinical trials for this group of patients," Dr Plotkin and coauthors write.

A major goal of the REiNS Collaboration is to develop standardized outcome measures for use in NF clinical trials. The collaborators are organized into seven working groups, focusing on imaging of tumor response, functional outcomes, visual outcomes, patient-reported outcomes, neurocognitive outcomes, and whole-body magnetic resonance imaging (MRI), and disease biomarkers. The new supplement includes initial working group reports addressing:

  • Patient-reported outcomes, especially pain.
  • Functional outcomes affecting vision -- important because of the high rate of tumors affecting the optic nerve in NF1.
  • Hearing and facial function outcomes, addressing the high rate of hearing loss and facial weakness in NF2.
  • Imaging tumor response -- MRI with volumetric analysis is recommended to show changes in tumor size.

By developing consensus outcome measures relevant to NF, the REiNS collaborators hope to promote rapid evaluation of treatments that may benefit individuals affected by these disorders. "Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate approval of drugs for patients with NF," Dr Plotkin and coauthors write.

They add that the recommendations will likely be modified over time, as more data on NF-specific endpoints become available. Future modifications to the recommendations and other updates will be shared with the NF research community through the REiNS website: http://www.reinscollaboration.org.


Story Source:

The above story is based on materials provided by Wolters Kluwer Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. E. Dombi, S. L. Ardern-Holmes, D. Babovic-Vuksanovic, F. G. Barker, S. Connor, D. G. Evans, M. J. Fisher, S. Goutagny, G. J. Harris, D. Jaramillo, M. A. Karajannis, B. R. Korf, V. Mautner, S. R. Plotkin, T. Y. Poussaint, K. Robertson, C.-S. Shih, B. C. Widemann. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology, 2013; 81 (Issue 21, Supplement 1): S33 DOI: 10.1212/01.wnl.0000435744.57038.af

Cite This Page:

Wolters Kluwer Health. "Common outcome measures required for neurofibromatosis clinical trials." ScienceDaily. ScienceDaily, 9 December 2013. <www.sciencedaily.com/releases/2013/12/131209105232.htm>.
Wolters Kluwer Health. (2013, December 9). Common outcome measures required for neurofibromatosis clinical trials. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2013/12/131209105232.htm
Wolters Kluwer Health. "Common outcome measures required for neurofibromatosis clinical trials." ScienceDaily. www.sciencedaily.com/releases/2013/12/131209105232.htm (accessed April 17, 2014).

Share This



More Mind & Brain News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Study On Artists' Brain Shows They're 'Structurally Unique'

Study On Artists' Brain Shows They're 'Structurally Unique'

Newsy (Apr. 17, 2014) — The brains of artists aren't really left-brain or right-brain, but rather have extra neural matter in visual and motor control areas. Video provided by Newsy
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) — A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Are School Dress Codes Too Strict?

Are School Dress Codes Too Strict?

AP (Apr. 16, 2014) — Pushing the limits on style and self-expression is a rite of passage for teens and even younger kids. How far should schools go with their dress codes? The courts have sided with schools in an era when school safety is paramount. (April 16) Video provided by AP
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) — A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins